Detalles de la búsqueda
1.
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Invest New Drugs
; 36(5): 848-859, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29349598
2.
Detection of truncated HER2 forms in formalin-fixed, paraffin-embedded breast cancer tissue captures heterogeneity and is not affected by HER2-targeted therapy.
Am J Pathol
; 183(2): 336-43, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23727348
3.
Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Carcinogenesis
; 34(9): 2031-8, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23698633
4.
Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis.
Cancers (Basel)
; 14(10)2022 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35625984
5.
Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.
Oncogene
; 40(15): 2651-2666, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33692466
6.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Clin Cancer Res
; 27(3): 807-818, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33122343
7.
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
ESMO Open
; 4(4): e000532, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31423336
8.
Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis.
Ann N Y Acad Sci
; 1130: 280-6, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18596360
9.
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.
Mol Cancer Ther
; 6(1): 93-100, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17237269
10.
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
Cancer Treat Rev
; 68: 111-123, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29944978
11.
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.
Mol Cancer Ther
; 17(7): 1464-1474, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29654069
12.
Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions.
Commun Biol
; 1: 28, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30271914
13.
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
PLoS One
; 12(5): e0177331, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28493933
14.
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Clin Cancer Res
; 11(14): 5300-9, 2005 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16033849
15.
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
Clin Cancer Res
; 11(9): 3503-13, 2005 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15867253
16.
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Cancer Res
; 63(21): 7436-42, 2003 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14612543
17.
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.
Cancer Res
; 62(4): 1057-62, 2002 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11861382
18.
Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity.
Biochem Pharmacol
; 63(3): 471-83, 2002 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11853698
19.
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
Cancer Treat Rev
; 39(8): 925-34, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23562214
20.
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
Mol Oncol
; 7(3): 580-94, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23474221